The colorectal cancer treatment market is expected to grow from US$ 18.810 billion in 2022 to US$ 23.978 billion by 2030; it is anticipated to record a CAGR of 3.1% from 2022 to 2030.

The growing market size is growing rapidly attributed to due to the increase in growing number of colorectal cancer cases and increasing approvals of for targeted therapy and immunotherapy for to treatment of colorectal cancer. In addition, strategic initiatives by companies to stay competitive in the market are fueling the market growth. A significant rise in revolutionary personalized medicines to address customer needs for the treatment of colorectal cancer is likely to bring new colorectal cancer treatment market trends during the forecast period.

Rising Incidence of Colorectal Cancer Cases is Driving the Colorectal Cancer Treatment Market Growth.

Colorectal cancer is a malignant tumor that occurs in colonic or rectal tissues. Lifestyle factors such as low intake of fruits and vegetables, smoking addiction, sedentary lifestyle, obesity, high intake of processed meats, and excessive alcohol consumption is are contributing to the growth of the colorectal cancer cases. It is the third most common type of cancer (excluding skin cancer) diagnosed yearly in the US. In 2023, the World Health Organization (WHO) stated that colorectal cancer is the 3rd most common cancer worldwide and is the 2nd leading cause of cancer-related deaths globally. As per the same source, about 10% of the total cases diagnosed globally are colorectal cancer cases. As per the American Cancer Society's estimated estimates, that about 106,000 new colon cancer cases and ~46,000 new rectal cancer cases were registered in the United StatesUS in 2023. As per the data provided by the European Cancer Information System, colorectal cancer accounted for about 12.7% of all new cancers diagnosed in 2020, and approximately 12.4% of total mortalities were caused by the colorectal cancer in 2020 in EU-27 countries. Due to this high prevalence, colorectal cancer is the second most frequently occurring cancer, after breast cancer, and the second leading cause of cancer-related deaths, after lung cancer. According to the International Agency for Research on Cancer & GLOBOCAN, ~1 million new colorectal cancer cases were reported in Asia in 2020. Japan, Malaysia, China, Singapore, Turkey, and Korea witnessed high prevalence rates as compared to the other countries in Asia Pacific. Additionally, by 2040, the global colorectal cancer burden is estimated to increase by 72% to more than 3 million new cases, posing a severe threat to human health. Thus, the rising incidence of colorectal cancer drives the colorectal cancer treatment market growth.

Based on geography, the colorectal cancer treatment market is segmented into North America (theUS, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). North America is the biggest contributor to the global colorectal cancer treatment market growth. Asia Pacific is predicted to show the highest CAGR in the market during 2022-2030. North America held the largest share of the global market in 2022 owing to increasing growing number of colorectal cancers, the increasing technological advancements, growing high prevalence of colorectal cancer in population people aged below 50 years, and the presence of key market players involved in new and existing product developments. In North America, the US held the largest share of the market in 2022.

World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and National Library of Medicine (NLM) are a few key primary and secondary sources referred to while preparing the report on the colorectal cancer treatment market.